E
CSTL icon

Ergoteles’s Castle Biosciences CSTL Stock Holding History

Ergoteles’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,400
Closed -$359K – 1299
2021
Q3 		$359K Buy
+5,400
New +$380K 0.01% 722
2021
Q2 		– Sell
-26,861
Closed -$1.84M – 1522
2021
Q1 		$1.84M Buy
+26,861
New +$2.02M 0.06% 290

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Ergoteles's CSTL Position: Q4 2021 in Review

Ergoteles sold out of Castle Biosciences (CSTL) in Q4 2021, closing a stake of 5,400 shares — an estimated $359K sold.

Ergoteles first reported a position in CSTL in Q1 2021 and held it in 2 quarters. The position peaked at $1.84M in Q1 2021. 159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

  • Ergoteles reported no remaining Castle Biosciences position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 5,400 Castle Biosciences shares in Q4 2021, an estimated $359K.
  • Ergoteles first reported a position in Castle Biosciences in Q1 2021 and held it in 2 quarters.
  • Ergoteles's Castle Biosciences position peaked at $1.84M in Q1 2021.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.